Regeneron, Rival Reach Settlement in Patent Dispute Over Eye Medication Biosimilar

By Editorial Team

Regeneron and a South Korea-based rival have reached a settlement to resolve a patent infringement case related to Regeneron’s leading eye medication, Eylea. The agreement brings an end to the legal battle that was filed in a West Virginia federal court.

The settlement between Regeneron Pharmaceuticals Inc. and Celltrion Inc. comes after Regeneron accused the South Korean company of infringing several patents covering Eylea, a key biotech product of Regeneron.

The patents in question include those related to the use of a VEGF antagonist for treating angiogenic eye disorders, VEGF antagonist formulations suitable for intravitreal administration, modified chimeric polypeptides with improved pharmacokinetic properties, enhanced expression and stability regions, and methods for producing aflibercept in chemically defined media with reduced variants.

The legal battle involved prominent law firms representing both parties, including Gemini Law, Hissam Forman, Kellogg Hansen, Paul Weiss, Williams & Connolly, and Willkie Farr.

The case was filed in the United States District Court for the Northern District of West Virginia, with the involvement of the Food and Drug Administration (FDA) due to the nature of the biosimilar medication at the center of the dispute.

Details of the settlement agreement, including any financial terms or licensing agreements, have not been disclosed publicly. The resolution of the case brings an end to the litigation process, allowing both companies to move forward without the burden of ongoing legal disputes.

For more information and updates on legal developments, subscribe to Law360 for comprehensive coverage of legal news and analysis.